How the Hormuz blockade became a prolonged war: pharma’s supply nightmare deepens as truce fails and strait closes again

The 21-mile-wide waterway that supplies Europe’s medicine cabinet is not reopening — it is effectively closed once more, live maritime tracking data and intelligence reports show. The crisis that began in February has evolved into an active theatre of war with no clear end in sight.
For nearly four months, from March to June 2026, the disruption was already severe. But the framework agreement hailed in mid-June did not hold, as Al Jazeera, Britannica and real-time vessel tracking services have since documented. As of 20 July, multiple trackers describe the Strait of Hormuz as “effectively closed” again; Iran has declared the previous memorandum “entirely suspended”; and US forces carried out a tenth consecutive night of strikes on Iran that same day, per briefings from US Central Command.
The failed truce: what happened to the “reopening”
On 17 June 2026 — not 15 June, as was previously reported — the US and Iran signed a 14-point deal brokered by Pakistan, known as the Islamabad Memorandum, the Pakistani Ministry of Foreign Affairs confirmed. The agreement was intended to restore shipping lanes and de-escalate tensions. Traffic never returned to normal, however: ship-tracking data cited by maritime security firms shows pre-war baselines of roughly 88 ships a day dropping to only about 28 a day even during the supposed ceasefire period.
At least five commercial vessels were attacked in the strait after the ceasefire took effect, Al Jazeera reported, a figure shipping insurers have since confirmed. By early-to-mid July, both sides had resumed active strikes against each other, according to statements from the US Department of Defense and Iranian state media. On 20 July, American forces carried out their tenth consecutive night of strikes on Iranian targets, US military press releases said. Tehran responded by declaring the Islamabad Memorandum “entirely suspended” — a statement broadcast on Iranian state television — effectively ending any pretense of a diplomatic resolution.
The current logistical and economic reality
The Council on Foreign Relations’ initial finding — commercial activity down 90% against pre-war levels by 16 March — now looks like a baseline for an even deeper collapse. Current traffic is so sporadic that shipping analysts are treating the strait as functionally closed, live tracking data indicates.
Brent crude, which had already surged past $100 a barrel in March, is spiking again in July following the truce’s collapse and the resumption of US strikes, Bloomberg commodity pricing shows. That sustained high-price environment is eroding the inventory buffers that Indian pharmaceutical manufacturers relied on during the first wave of disruption, chemical industry economists say.
The per-shipment surcharges of $4,000 to $8,000 and the 23% drop in March exports that Pharmexcil, India’s pharmaceutical export promotion council, recorded earlier this year are now being compounded by a second, more severe wave of rerouting, the council says. Air cargo rates out of India — which had already increased by as much as 350% in March — remain elevated and volatile as alternative airspace becomes contested, freight forwarders cited by The Economic Times report.
Alternative routes are overwhelmed, not strategic
The alternative routes previously discussed — the Cape of Good Hope and the India-Oman economic corridor — are no longer structural hedges but overwhelmed contingency paths, shipping analysts say. The India-Oman economic partnership, which entered into force on 1 June 2026, provides zero-duty access, the Indian Ministry of Commerce notes, but operation alising the route at scale requires months of lead time, not days, according to trade logistics experts. With the strait closed indefinitely, container vessels are now making long-term commitments to the African route — adding roughly 4,000 miles and up to two weeks to transit times, maritime data shows — Maersk and other shipping lines confirm.

For temperature-sensitive biologics — monoclonal antibodies, vaccines, insulin — the current uncertainty is catastrophic, cold-chain logistics providers warn: product integrity cannot be guaranteed on circuitous, unproven routes with fluctuating refuelling stops.

Financial resilience is fraying, not holding
The major Indian manufacturers — Dr. Reddy’s, Sun Pharma and Cipla — posted resilient numbers for the March-May quarter, absorbing costs without publicly flagging the war as materially damaging, Qyobo’s July 2026 financial recap found. But those results reflected only the first wave of disruption and existing inventory stockpiles, industry analysts caution. The sustained closure — now entering a second wave with higher oil prices and no diplomatic horizon — means those absorbed costs will inevitably be passed on to healthcare systems, insurers and patients, procurement executives at European hospital groups say.
The European Commission’s Critical Medicines Act remains a long-term policy objective. France’s €1.5 billion Health Sovereignty initiative and Germany’s €1.2 billion resilience fund — per the French Ministry of Health and Germany’s Federal Ministry for Economic Affairs, respectively — were designed for short-to-medium-term shocks. Pharmaceutical security experts argue these funds are wholly inadequate for a prolonged war scenario in which the strait may stay effectively closed for the remainder of 2026.
What comes after — when there is no reopening in sight
The question for Europe is no longer “when will the strait reopen?” but “how does the continent secure essential medicines during an active, ongoing military conflict?” — that’s how geopolitical risk consultancies are now framing it. The tenth consecutive night of strikes on 20 July indicates the US has no intention of de-escalating in the immediate future, US Central Command’s own reporting suggests. Iran’s suspension of the Islamabad Memorandum is total, according to Iranian state media, and its naval forces have declared the strait a high-risk exclusion zone.
The assumption that pharmaceutical supply chains could weather a 90-day disruption has been proven dangerously optimistic, supply chain resilience experts say. With the strait effectively closed as of yesterday, the crisis once framed as a tail-risk event is now the new normal for European pharmaceutical procurement — and, on all available intelligence, it is getting worse, not better.